Lupin Reports Strong Q4 FY2025 Performance with 71% Surge in Net Profit

Lupin Limited reported a robust financial performance for FY2025, with consolidated sales rising by 12.9% year-on-year to ₹221,921 million from ₹196,563 million in FY2024. The company saw a strong 39.4% increase in EBITDA, reaching ₹54,792 million, while EBITDA margin improved significantly to 24.7% from 20% the previous year. Profit before tax (PBT) jumped 65.8% to ₹40,150 million, and net profit (PAT) rose by 70.8% to ₹33,063 million. This impressive performance led the Board to recommend a 600% dividend based on Lupin’s positive long-term outlook.

Quarterly Highlights – Q4 FY2025

In the fourth quarter, revenue increased by 13.6% year-on-year to ₹55,622 million. EBITDA grew by 34.3% to ₹13,781 million, and PAT more than doubled, rising 112.5% to ₹7,824 million. While sales slightly declined quarter-on-quarter by 1.0%, key profitability metrics remained strong. Gross profit stood at ₹38,760 million, with a gross margin of 69.7%. Personnel costs accounted for 18% of sales, and manufacturing and other expenses made up 30.3%. R&D investment for the quarter was ₹5,346 million, or 9.6% of sales.

Read More, BEML Shares to Trade Ex-Date on May 15: Interim Dividend of ₹10. 

Sales Breakdown by Region

During FY2025, North America remained Lupin’s largest market, contributing ₹83,950 million (up 15.9%), followed by India with ₹75,773 million (up 13.8%). Other developed markets grew significantly by 23.4% to ₹25,072 million, while emerging markets rose 6.8% to ₹25,354 million. Total formulation sales stood at ₹210,149 million, while API sales grew modestly by 3.1% to ₹11,772 million.

In Q4 FY2025, North America led with ₹22,618 million in sales (up 19.0% YoY), India followed with ₹17,113 million (up 6.9% YoY), and Other Developed Markets saw the highest growth at 30%, reaching ₹6,915 million. API sales, however, declined 10.3% YoY to ₹2,316 million.

Operational and Market Highlights

In North America, Lupin generated USD 925 million in FY2025 sales, up from USD 815 million in FY2024. The company launched 2 new products and received 7 ANDA approvals from the U.S. FDA during the quarter. Lupin now has 138 generics in the U.S. and is ranked third in the U.S. generic market by prescriptions. In India, the company launched four new brands in Q4 and maintained its position as the 8th largest pharma player. In other developed markets, Germany and Australia saw strong sales growth, with Germany reaching EUR 52 million and Australia AUD 119 million for FY2025.

Research and Development

Lupin increased its investment in R&D to ₹17,672 million for the full year, which was 8.0% of its total sales. As of March 31, 2025, the company has filed 441 ANDAs with the U.S. FDA and received 340 approvals. It also has 47 First-to-File (FTF) filings, including 16 exclusive ones, and 157 cumulative Drug Master Files (DMFs) filed in the U.S.

About Lupin

Lupin Limited is a global pharmaceutical company based in Mumbai, India. It offers a wide range of branded and generic formulations, complex generics, biotech products, and APIs. With a strong presence in over 100 countries, Lupin has 15 manufacturing sites, 7 research centres, and employs over 23,000 professionals. It operates through subsidiaries such as Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Lupin share price is trading at ₹2,076.40 as of 9:29 AM on May 15, up by ₹5.00 or 0.24% for the day. The stock opened at ₹2,100.00, reaching a high of ₹2,118.90 and a low of ₹2,063.80 during the session. 

With a market capitalisation of ₹94,690 crore, Lupin has a price-to-earnings (P/E) ratio of 33.08 and offers a dividend yield of 0.39%. The stock's 52-week high is ₹2,402.90, while the 52-week low stands at ₹1,493.30. The company has declared a quarterly dividend of ₹2.02 per share.

Conclusion

Lupin’s strong FY2025 performance underscores its resilience and strategic execution across key markets. With robust product launches, margin expansion, and growing global presence, the company is well-positioned for continued growth and value creation in the coming years.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.      

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.